Arena Pharmaceuticals, Inc.
) announced that partner
) has increased the sales force of their obesity drug, Belviq, by
50% to approximately 600. With this increase, Eisai expects to
reach approximately 92,000 physicians in the U.S.
Apart from generating awareness about Belviq, Eisai is also working
on expanding reimbursement for Belviq. Eisai estimates that Belviq
coverage in the U.S. has improved. The company estimates that the
commercially insured population with coverage for Belviq has
In the first quarter of 2014, Arena Pharma recorded Belviq sales of
$2.9 million (including $0.2 million from the 15-day free trial
voucher redemption). Total prescriptions for Belviq increased 31%
from the preceding quarter to approximately 77,000.
Arena Pharma and Eisai are evaluating Belviq for additional
indications. These include smoking cessation (phase II study
ongoing) as well as safety of Belviq when administered in
combination with phentermine (12-week pilot study). Additionally,
the companies are studying Belviq's effects on diabetes and
cardiovascular outcomes (CAMELLIA study).
Arena Pharma and Eisai are leaving no stone unturned to make the
drug a success. We are positive on the beefed up sales force for
Belviq. The additional promotion should increase awareness about
the product and help Belviq sales gain momentum. Arena Pharma's
growth is highly dependent on Belviq, the company's sole marketed
Currently available therapies for obesity include
Both Arena Pharma and Eisai currently carry a Zacks Rank #3 (Hold).
Some better ranked stocks in the health care sector include
Osiris Therapeutics, Inc.
) carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
VIVUS INC (VVUS): Free Stock Analysis Report
ARENA PHARMA (ARNA): Free Stock Analysis Report
OSIRIS THERAPTC (OSIR): Free Stock Analysis
EISAI CO LTD (ESALY): Get Free Report
To read this article on Zacks.com click here.